Effect of Early Spironolactone Treatment on Albuminuria in Patients with CKD and Hypertension: A Randomized Controlled Trial

Background: Recent research emphasizes non-steroidal mineralocorticoid receptor antagonists (MRAs) for slowing chronic kidney disease (CKD) progression and reducing albuminuria. However, there is limited research on the efficacy of spironolactone, a more accessible and low-cost steroidal MRA. Methods: This randomized controlled trial was conducted at Bhumibol Adulyadej Hospital, Bangkok, Thailand, from October 2023 to February 2024. Participants had hypertension and CKD stage 2-3 (eGFR 30-89 ml/min/1.73 m2) and were already receiving ACEI or ARB medication. Eleven patients were enrolled: five received spironolactone, and six did not. Both groups received standard hypertension care. Follow-up evaluations were conducted at 3 months. Results: Patients receiving spironolactone showed a mean decrease in urinary albumin-to-creatinine ratio (UACR) of 655.00 ± 621.82 mg/g, compared to 320.50 ± 504.87 mg/g in the control group, resulting in a difference of 295.92 mg/g (95% CI: -942.33 to 350.49; p = 0.370). The change in eGFR was -8.64 ± 9.12 ml/min/1.73 m2 in the spironolactone group and -3.38 ± 14.62 ml/min/1.73 m2 in the control group, with a difference of -5.26 ml/min/1.73 m2 (95% CI: -16.77 to 6.69; p = 0.400). The change in systolic blood pressure (SBP) was -21.80 ± 20.64 mmHg vs. -22.00 ± 24.79 mmHg (difference: 0.20 mmHg, 95% CI: -39.74 to 10.49; p = 0.254). The mean serum creatinine levels were 1.61 ± 0.90 mg/dL in the spironolactone group and 1.10 ± 0.14 mg/dL in the control group, differing by 0.51 mg/dL (95% CI: 0.07 to 0.95; p = 0.009). The mean potassium levels were 4.90 ± 0.43 mmol/L and 4.23 ± 0.41 mmol/L, respectively, differing by 0.67 mmol/L (95% CI: 0.22 to 1.08; p = 0.003). Conclusion: Spironolactone did not significantly decrease albuminuria in hypertensive CKD patients already on ACEI or ARB therapy but was associated with increased potassium and creatinine levels. The study's findings are limited by the small sample size and short duration.

Authors

Institutions

Publication Details

Journal
Journal of the American Society of Nephrology
Published
2024-10-01
DOI
https://doi.org/10.1681/asn.20248c4nxfe4
Primary Topic
Hormonal Regulation and Hypertension
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Effect of Early Spironolactone Treatment on Albuminuria in Patients with CKD and Hypertension: A Randomized Controlled Trial

Kamolwan Pakchotanon, Nattakarn Anantasamit
Journal of the American Society of Nephrology
Hormonal Regulation and Hypertension
article

Effect of Early Spironolactone Treatment on Albuminuria in Patients with CKD and Hypertension: A Randomized Controlled Trial

Kamolwan Pakchotanon, Nattakarn Anantasamit
article en

Abstract

Background: Recent research emphasizes non-steroidal mineralocorticoid receptor antagonists (MRAs) for slowing chronic kidney disease (CKD) progression and reducing albuminuria. However, there is limited research on the efficacy of spironolactone, a more accessible and low-cost steroidal MRA. Methods: This randomized controlled trial was conducted at Bhumibol Adulyadej Hospital, Bangkok, Thailand, from October 2023 to February 2024. Participants had hypertension and CKD stage 2-3 (eGFR 30-89 ml/min/1.73 m2) and were already receiving ACEI or ARB medication. Eleven patients were enrolled: five received spironolactone, and six did not. Both groups received standard hypertension care. Follow-up evaluations were conducted at 3 months. Results: Patients receiving spironolactone showed a mean decrease in urinary albumin-to-creatinine ratio (UACR) of 655.00 ± 621.82 mg/g, compared to 320.50 ± 504.87 mg/g in the control group, resulting in a difference of 295.92 mg/g (95% CI: -942.33 to 350.49; p = 0.370). The change in eGFR was -8.64 ± 9.12 ml/min/1.73 m2 in the spironolactone group and -3.38 ± 14.62 ml/min/1.73 m2 in the control group, with a difference of -5.26 ml/min/1.73 m2 (95% CI: -16.77 to 6.69; p = 0.400). The change in systolic blood pressure (SBP) was -21.80 ± 20.64 mmHg vs. -22.00 ± 24.79 mmHg (difference: 0.20 mmHg, 95% CI: -39.74 to 10.49; p = 0.254). The mean serum creatinine levels were 1.61 ± 0.90 mg/dL in the spironolactone group and 1.10 ± 0.14 mg/dL in the control group, differing by 0.51 mg/dL (95% CI: 0.07 to 0.95; p = 0.009). The mean potassium levels were 4.90 ± 0.43 mmol/L and 4.23 ± 0.41 mmol/L, respectively, differing by 0.67 mmol/L (95% CI: 0.22 to 1.08; p = 0.003). Conclusion: Spironolactone did not significantly decrease albuminuria in hypertensive CKD patients already on ACEI or ARB therapy but was associated with increased potassium and creatinine levels. The study's findings are limited by the small sample size and short duration.

Journal of the American Society of NephrologyVol. 35(10S)
Bhumibol Adulyadej Hospital (TH)
Good health and well-being
Openalex Percentile: Top 69%
Hormonal Regulation and Hypertension
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Effect of Early Spironolactone Treatment on Albuminuria in Patients with CKD and Hypertension: A Randomized Controlled Trial — Kamolwan Pakchotanon, Nattakarn Anantasamit · Journal of the American Society of Nephrology (2024) | TGRS Research Map | TGRS